JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Начало・Списък с акции・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

11.46 -1.04

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

11.34

Максимум

11.62

Ключови измерители
By Trading Economics
Приходи	-1.8M 22M
Продажби	7.5M 70M
P/E Средно за сектора	24.362 34.393
Марж на печалбата	30.729
Служители	130
EBITDA	-1.8M 20M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+6.47% upside

Дивиденти
By Dow Jones
Следващи печалби	6.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	306M 1.5B
Предишно отваряне	12.5
Предишно затваряне	11.46

Настроения в новините

By Acuity

91%

4 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

8.1 / 8.21 Подкрепа & съпротива

Aurinia Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.08.2025 г., 17:49 ч. UTC

Значими двигатели на пазара

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11.08.2025 г., 17:18 ч. UTC

Значими двигатели на пазара

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11.08.2025 г., 16:25 ч. UTC

Печалби

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11.08.2025 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as Yen Weakens -- Market Talk

11.08.2025 г., 23:42 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

11.08.2025 г., 23:42 ч. UTC

Пазарно говорене

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11.08.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11.08.2025 г., 23:32 ч. UTC

Пазарно говорене

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11.08.2025 г., 23:02 ч. UTC

Пазарно говорене

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings 2Q Rev $577.9M >BKKT

11.08.2025 г., 20:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11.08.2025 г., 20:22 ч. UTC

Печалби

Exodus Movement 2Q Rev $25.8M >EXOD

11.08.2025 г., 20:14 ч. UTC

Пазарно говорене

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11.08.2025 г., 19:12 ч. UTC

Пазарно говорене

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11.08.2025 г., 18:56 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11.08.2025 г., 18:31 ч. UTC

Пазарно говорене

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11.08.2025 г., 17:43 ч. UTC

Пазарно говорене

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11.08.2025 г., 17:28 ч. UTC

Пазарно говорене

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11.08.2025 г., 17:16 ч. UTC

Пазарно говорене

Commodity Longs Fall to 11-Month Low -- Market Talk

11.08.2025 г., 16:42 ч. UTC

Придобивния, сливания и поглъщания

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11.08.2025 г., 16:27 ч. UTC

Придобивния, сливания и поглъщания

BBVA Says Sabadell Offer Remains in Effect

11.08.2025 г., 16:26 ч. UTC

Придобивния, сливания и поглъщания

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11.08.2025 г., 16:25 ч. UTC

Придобивния, сливания и поглъщания

Banco de Sabadell Announced TSB Sale on July 1

11.08.2025 г., 16:25 ч. UTC

Придобивния, сливания и поглъщания

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Сравнение с други в отрасъла

Ценова промяна

Aurinia Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

6.47% нагоре

12-месечна прогноза

Среден 12.17 USD 6.47%

Висок 17 USD

Нисък 9 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Aurinia Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Aurinia Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

8.1 / 8.21Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Настроение

By Acuity

4 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.